11.36
0.29 (2.62%)
| Previous Close | 11.07 |
| Open | 11.22 |
| Volume | 752,950 |
| Avg. Volume (3M) | 1,366,263 |
| Market Cap | 838,653,184 |
| Price / Sales | 3.45 |
| Price / Book | 2.44 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | -83.39% |
| Operating Margin (TTM) | -85.45% |
| Diluted EPS (TTM) | -2.63 |
| Quarterly Revenue Growth (YOY) | 62.70% |
| Total Debt/Equity (MRQ) | 31.15% |
| Current Ratio (MRQ) | 3.45 |
| Operating Cash Flow (TTM) | 25.97 M |
| Levered Free Cash Flow (TTM) | -17.73 M |
| Return on Assets (TTM) | -16.27% |
| Return on Equity (TTM) | -43.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Schrodinger, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.63 |
|
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.63% |
| % Held by Institutions | 101.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gates Foundation Trust | 31 Dec 2025 | 6,981,664 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Keybanc, 120.07%) | Buy |
| Median | 24.00 (111.27%) | |
| Low | 18.00 (UBS, 58.45%) | Hold |
| Average | 22.33 (96.57%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 18.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Keybanc | 08 Jan 2026 | 25.00 (120.07%) | Buy | 18.61 |
| TD Cowen | 08 Jan 2026 | 24.00 (111.27%) | Buy | 18.61 |
| UBS | 07 Jan 2026 | 18.00 (58.45%) | Hold | 18.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities |
| 09 Jan 2026 | Announcement | Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |